Therapeutic options after first line treatment failure
|
|
- Valentine Lane
- 6 years ago
- Views:
Transcription
1 Therapeutic options after first line treatment failure Orlando ASH 215 Guillermo Garcia-Manero MD Professor of Medicine Chief Section of MDS Deputy Chair, Translational Research Department of Leukemia MD Anderson Cancer Center University of Texas Houston, TX
2 DISCLOSURE I have no relevant financial relationships to disclose.
3 What are the major needs in MDS? (problems that limit significant cure rate) Identification of poor prognosis lower risk patients By default sparing patients with no need of therapy Concept of early intervention Development of new targeted therapies for patients with lower risk MDS Development of new therapies for patients with higher risk MDS Understanding mechanisms of resistance to epigenetic modulators in MDS Understanding mechanisms of transformation to AML Incorporation of allosct in MDS Minimizing risk of relapse post allosct in MDS
4 Natural history of MDS after incorporation of HMAs Prodrome LR-MDS Untreated HMA? lenalidomide HMA failure? HR-MDS Untreated HMA AML-like SCT HMA failure AML-like?? AML HMA lower risk failure survival: months HMA higher risk failure survival: 4-6 months Jabbour. Cancer 215; Jabbour. Cancer 21
5 H3K4me3 Chip-seq Strategy in MDS MDS patient s BM Control BM CD34+ CD34+ CD34- CD34- Ch-IP with H3K4-3Me Antibody Solexa Sequencing of Specific H3K4-3Me Rich Chromatin Fragments Bio-info analysis MDS specific biomarkers (Potential Specific Epigenetic Change in MDS) Wei. Leukemia 213.
6 relative level of RNA relative level of RNA relative level of RNA H3K4m3 CHIP-Seq: Data Analysis & Validation criteria for MDS specific H3K4me3 peak selection +/- 2kb to TSS of a known gene MDS vs control > 3 fold p value < 1-6 C5AR1 MDS control promoter H3K4me3 enrichment relative level of RNA RNA expression C5AR1 N=94 N=8 MDS control PTAFR MDS control promoter H3K4me3 enrichment relative level of RNA RNA expression PTAFR N=1 N=9 MDS control FPR1 & FPR2 MDS control FPR1 N=65 N=4 MDS control FPR2 N=89 N=8 AQP9 MDS control TYROBP MDS relative level of RNA AQP9 N=87 N=4 MDS control TYROBP N=1 N= control 1 Wei. Leukemia MDS control 5 MDS control
7 H3K4me3 Associated Gene Activation in CD34+ Cells of MDS MDS BM CD34- MDS BM CD genes 156 genes CFD SLC11A1 Wei. Leukemia. 213
8 H3K4me3-associated Gene Activation in MDS CD34+ Cells targets an Innate Immunity Like Pathway Ingenuity Pathway Analysis predicted NFkB-centered signal activation = with reported involvement in innate immune signaling activation Wei. Leukemia. 213
9 Overexpression of Other Innate Immunity Like Signaling Components in MDS BM CD34+ (non-chip-seq identified) CHIP-Seq gene products Toll like receptors (TLR) TLR2/ TLR1 TLR2/ TLR6 Genes examined in MDS BM CD34+ cells TLR1, 2, 3, 4, 6, 7, 8, 9, MYD88, IL-8 expression level in primary MDS BM CD34+ cells MYD fold NF-kB I-kB p5 p65 IL8 receptor IL fold 5.5 fold 2 fold 138 fold IL8 TLR1 TLR2 TLR6 MYD88 IL-8 MDS bone marrow CD34+ Genes showing potential prognostic value TLR1 and MYD88 expression levels negatively associate with overall survival (OS) in MDS patients Wei. Leukemia. 213
10 TLR2 Stimulation Activates Histone Demethylase JMJD3 De Santa F et al Cell 27 JMJD3 is Overexpressed in MDS CD34+ Cells Wei. Leukemia. 213
11 Relative Expression Innate Immunity Genes & Patient Response to Epigenetic Targeting Drugs SAHA/ AZA 2 15 TLR C5AR FPR D D5 D21 D28 Resistance Sensitive N=11 N=7 FPR2 D D5 D21 D D D5 D21 D28 Resistance Sensitive TYROBP D D5 D21 D28 D D5 D21 D28 Resistance Sensitive Yang H et al Resistance Sensitive Resistance Sensitive
12 Cellular Immune Dyregulation in MDS MDS Immunosuppression CTL Th17 Tregs DC Macrophage Adaptive Immune Responses B Cells NK Selective Leukemic Clone Growth Tumor Immune Evasion Mechanisms: 1. Inhibitory B7 expression by tumor, APC and stroma cells. 2. APC 3. Treg.
13 What about cellular immunity? Aberrant up-regulation of PD-L1, PD-L2, PD-1 and CTLA4 in CD34+ cells from MDS, CMML and AML. Yang et al Leukemia 214
14 Relative expression RelativeExpression Relative expression Relative Expression Dynamics of PD-L1, PD-L2, PD-1 and CTLA4 expression in patients treated with different forms of epigenetic therapy. PD-L1 CTLA Days on Therapy Days on Therapy PD-L2 2 P D Days on Therapy D a y s o n T h e r a p y Yang et al Leukemia 214
15 Epitargeting of immune pathways in MDS 2. Molecular Mechanisms: Searching endogenous PAMP/ DAMP that activates innate immune signaling and involves in MDS pathogenesis 3. Evaluate Therapeutic Potential of targeting innate immune signaling in MDS 1. Molecular Mechanisms: Interaction between innate immune signal and other genetic lesions in MDS pathogenesis Gomez-Ganan. Leukemia 215.
16 Adult murine hematopoiesis LT-HSC Lin - ckit + sca1 + CD34 - CD135 - HSC COMPARTMENT = KSL ST-HSC Lin - ckit + sca1 + CD34 + CD135 - Lin - ckit + sca1 + CD34 + CD135 + MYELOID PROGENITOR COMPARTMENT = KL Lin - ckit + sca1 - CD34 + CD16/32 - CMP Lin - ckit + sca1 - MEP Lin - ckit + sca1 - CD34 - CD16/32 - CD34 + CD16/32 + MPP GMP LMPP Lin - ckit + sca1 + CD34 + CD135 bright CLP LYMPHOID PROGENITOR COMPARTMENT ERYTHROCYTES PLATELETS GRANULOCYTES MONOCYTES PRO T-CELL PRO B-CELL Modified from Iwasaki H et al. Immunity 27
17 [H g b ] ( g / d L ) C e ll c o u n t s (1 3 / m m 3 ) C e ll c o u n t s (1 3 / m m 3 ) C e ll c o u n t s (1 3 / m m 3 ) Short-term in TERT-ER mice: effect Aza on CBC E ffe c t o f 7 -d a y A Z A tr e a tm e n t o n W B C c o u n ts in T E R T -E R m ic e E ffe c t o f 7 -d a y A Z A tr e a tm e n t o n n e u tro p h il c o u n ts in T E R T -E R m ic e **** B a s e lin e 1 w e e k ** **** B a s e lin e 1 w e e k * 5.5 V e h ic le A Z A V e h ic le A Z A G G 5 E ffe c t o f A Z A tre a tm e n t o n h e m o g lo b in le v e ls in T E R T -E R m ic e. V e h ic le A Z A V e h ic le A Z A G G 5 E ffe c t o f 7 -d a y A Z A tr e a tm e n t o n p la te le t c o u n ts in T E R T -E R m ic e *** ** B a s e lin e 1 w e e k **** *** B a s e lin e 1 w e e k V e h ic le A Z A V e h ic le A Z A V e h ic le A Z A V e h ic le A Z A G G 5 N=2 Colla. Cancer Cell 215; Gomez-Ganan poster 2852 Sunday G G 5
18 C e ll n u m b e r (w e ig h t-n o r m a liz e d a n d r e la tiv e to C o n tr o l G ) C e ll n u m b e r (w e ig h t-n o r m a liz e d a n d r e la tiv e to C o n tr o l G ) C e ll n u m b e r (w e ig h t-n o r m a liz e d a n d r e la tiv e to C o n tr o l G ) C e ll n u m b e r (w e ig h -n o r m a liz e d a n d r e la tiv e to C o n tr o l G ) Short-term in TERT-ER mice: effect Aza on HSPC L T -H S C S T -H S C * V e h ic le A Z A V e h ic le A Z A V e h ic le A Z A V e h ic le A Z A G G 5 G G 5 C M P G M P 1 5 **** **** ** **** ** **** V e h ic le A Z A V e h ic le A Z A V e h ic le A Z A V e h ic le A Z A G G 5 N=2 Colla. Cancer Cell 215; Gomez-Ganan poster 2852 Sunday G G 5
19 Genomics of MDS Papaemmanuil et al Blood 213;122:
20 Clonal Progression from Myelodysplastic Syndrome (MDS) to Secondary Acute Myeloid Leukemia (saml). Walter MJ et al. N Engl J Med 212;366:
21 Daver et al. AJH 213 Flt3 alterations in MDS
22 Effect of acquisition of Flt3 or Ras mutations in MDS Probability of Transformation-free Survival Non-FLT3/RAS FLT3/RAS Time (Months) Takahashi. Leukemia 214
23 Ravandi. Blood 213 5AZA + Sorafenib Outcomes and Survival 46%
24 Lower risk non-hma failure
25 Proportion of patients Proportion of patients Results: AML-Free Survival by CyR in Patients With Isolated del(5q) and del(5q) + 1 Additional Abnormality Isolated del(5q) (n = 13) del(5q) + 1 additional abnormality (n = 32) 1..8 CyR Responder Non-responder Log-rank P = CyR Responder Non-responder Log-rank P = Median AML-free survival, months (95% CI) Major + Minor 59.9 (43.2 NR) Non-responder 36.7 ( ) Time to AML or death (months).2 Median AML-free survival, months (95% CI) Major + Minor 58.1 (34.8 NR) Non-responder 3.7 ( ) Time to AML or death (months) For the risk of AML transformation or death, CyR was associated with a 41% reduction (95% CI.38.92; P =.19) in patients with isolated del(5q) and a 58% reduction (95% CI ; P =.56) in patients with del(5q) + 1 additional abnormality, compared with no CyR Sekeres MA, et al. ASH 213; abstract 39.
26 Low dose DAC in LR MDS: Transfusion Independence Rate Arm A (Daily) N(%) Arm B (Weekly) N (%) RBC Transfusion Independence 2 (62.5) 15 (68.2) Platelet Transfusion Independence 22 (68.8) 18 (81.8) RBC/PLT Transfusion Independence 2 (62.5) 13 (59.1) Garcia-Manero JCO 213
27 Disposition Phase 1 Oral Aza Study Response to Therapy (N=41) Garcia-Manero JCO 211 MDS (N=29) N (%) CMML (N=4) N (%) AML (N=8) N (%) Ongoing 8 (28) 2 (5) 2 (25) Terminated 21 (72) 2 (5) 6 (75) Median duration of oral therapy, # of cycles, (range) 6. (1 23+) 7. (3 17+) 4.5 (1 14+) Cycle 7 Response Assessment* 13 (45) 2 (5) 2 (25) CR / PR / HI 4 (31) 1 (5) () SD 8 (61) 1 (5) 2 (1) Progression 1 (8) () () * IWG 23 or 26 Subjects did not meet criteria for progression or response by IWG 23
28 Lower risk HMA failure
29 LR MDS post HMA Failure. Outcome n events mos Median follow-up: 16 (1-8) months Median TFS and OS: 15 and 17 months Jabbour et al Cancer 215
30 Dual Inhibition of p38 and Tie2 by ARRY-614 p38 MAPK in MDS Stress/Inflammatory Stimuli (Cytokines, Hypoxia, FasL) Tie2 in MDS Emerging Target Ang-1 Ang-2 TNF-α, IL-6, Chemokines Decreased RBC, WBC, platelets p38 Apoptosis Pleiotropic effects on Progenitors and AML blasts Major regulator of the cellular pathways which sense stress Over-activated, leading to inappropriate production of myelosuppressive cytokines Garcia-Manero et al. Clin Cancer Res 215 Dysregulated, may be a survival factor for AML blast Increased signaling associated with poor prognosis 3
31 ARRY-614 Prior Therapies N = 71 Median prior therapies: 3 (range -6; 5 pts with no prior MDS therapies) % of Patients Azacitidine Only Decitabine Only Aza and Decitabine HMA ESA Lenalidomide G/GM-CSF Immunosuppression Other Investigational* ATG and/or prednisone includes cyclosporine, cytarabine, valproic acid, cladribine, mitoxantrone, rituximab, dexamethasone *includes siltuximab, HDAC inhibitors, hedgehog inhibitor, TXA127, Garcia-Manero et al. Clin Cancer Res 215
32 Epitargeting of immune pathways in MDS 2. Molecular Mechanisms: Searching endogenous PAMP/ DAMP that activates innate immune signaling and involves in MDS pathogenesis 3. Evaluate Therapeutic Potential of targeting innate immune signaling in MDS 1. Molecular Mechanisms: Interaction between innate immune signal and other genetic lesions in MDS pathogenesis Gomez-Ganan. Leukemia 215.
33 Higher risk HMA failure
34 Outcome in MDS post hypomethylating failure Jabbour. Cancer 21
35 Overall Survival and Subgroup Analysis from a Randomized Phase III Study of Intravenous Rigosertib vs Best Supportive Care in Patients with Higher-risk Myelodysplastic Syndrome After Failure of Hypomethylating Agents (ONTIME Trial of ON 191) G. Garcia-Manero, P. Fenaux, A. Al-Kali, M. R. Baer, M. Sekeres, G. Roboz, G. Gaidano, B. Scott, P. Greenberg, U. Platzbecker, D. P. Steensma, S. Kambhampati, L. Godley, R. Collins, E. Atallah, F. Wilhelm, I. Darnis-Wilhelm, N. Azarnia, M. Maniar, L. R. Silverman, for the ONTIME Investigators ASH
36 ONTIME Trial: Primary Efficacy Results ITT ASH
37 ONTIME Trial: Median Overall Survival for Pts with Primary HMA Failure - Blinded, Centralized Assessment ASH 214 Per Prebet 211, Primary HMA Failure was defined as either no response to or progression during HMA therapy 37
38 Clofarabine Plus Low-Dose Cytarabine For The Treatment Of Patients With higher-risk Myelodysplastic Syndrome Who Have Relapsed Or Are Refractory To Hypomethylating Agent Jabbour E, Sasaki K, Daver N, Pemmaraju N, Jain N, Kadia T, DiNardo C, Ravandi F, Miller D, Maduike R, Borthakur G, Konopleva M, Faderl S, O Brien S, Cortes J, Kantarjian H, Garcia-Manero G Department of Leukemia at MD Anderson Cancer Center Houston, Texas ASH 214
39 CLO and LDAC in HR MDS post HMA. Response (N=61) Best Response N (%); Median [range] Complete response 1 (15) Marrow CR 9 (14) CRp 3 (5) Partial response 1 (2) Hematologic improvement 4 (6) Overall response rate 27 (44) # Cycles to best response 1 [1-7] Early death 1 (2) ASH 214
40 CLO and LDAC in HR MDS post HMA. MVA for Response and Survival Multivariate analysis Response Survival Parameter OR P HR P Cyto Complex vs. No Plt 3 vs. >3 NA NS PS 2 vs. <2 NA NS 5.5 <.1 Response vs. Non-Response NA NS 7.1 <.1 Prior response to HMA NA NS NA NS ASH 214
41 CLO and LDAC in HR MDS post HMA. Survival by Response Status ASH 214
42 Aberrant up-regulation of PD-L1, PD-L2, PD-1 and CTLA4 in CD34+ cells from MDS, CMML and AML. Yang et al Leukemia 214
43 Examples of clinical trial options Genomic annotation: IDH1, IDH2, RAS, Flt-3 PD1/PDL1 combinations Toll-like receptor inhibitors (OPN-35) Oral azacitidine (CC-486) Bortezomib Omacetaxine FF-51
44 Guillermo Garcia-Manero
Yue Wei 1, Rui Chen 2, Carlos E. Bueso-Ramos 3, Hui Yang 1, and Guillermo Garcia-Manero 1
Genome-wide CHIP-Seq Analysis of Histone Methylation Reveals Modulators of NF- B Signaling And the Histone Demethylase JMJD3 Implicated in Myelodysplastic Syndrome Yue Wei 1, Rui Chen 2, Carlos E. Bueso-Ramos
More informationDepartment of Leukemia, The University of Texas M.D. Anderson Cancer Center, Houston, Texas; 2 Sunesis Pharmaceuticals, Inc, South San Francisco
Phase I/II Study of Vosaroxin and Decitabine in Newly Diagnosed Older Patients with Acute Myeloid Leukemia (AML) and High Risk Myelodysplastic Syndrome (MDS) Naval Daver 1, Hagop Kantarjian 1, Guillermo
More informationDepartment of Leukemia, The University of Texas M.D. Anderson Cancer Center, Houston, Texas; 2 Sunesis Pharmaceuticals, Inc, South San Francisco
Phase I/II Study of Vosaroxin and Decitabine in Newly Diagnosed Older Patients with Acute Myeloid Leukemia (AML) and High Risk Myelodysplastic Syndrome (MDS) Naval Daver 1, Hagop Kantarjian 1, Guillermo
More informationLow Risk MDS Scoring System. Prognosis in Low Risk MDS. LR-PSS Validation 9/19/2012
Advances in MDS What s on the Horizon Tapan M. Kadia, MD Department of Leukemia MD Anderson Cancer Center Outline Newer Prognostic Systems Hypomethylating agent failures Newer Treatment approaches Role
More informationA Phase II Study of the Combination of Oral Rigosertib and Azacitidine in Patients with Myelodysplastic Syndromes (MDS)
A Phase II Study of the Combination of Oral Rigosertib and Azacitidine in Patients with Myelodysplastic Syndromes (MDS) Shyamala C. Navada, MD 1, Lewis R. Silverman, MD 1, Katherine Hearn, RN 2, Rosalie
More informationAcute Myeloid Leukemia
Acute Myeloid Leukemia Pimjai Niparuck Division of Hematology, Department of Medicine Ramathibodi Hospital, Mahidol University Outline Molecular biology Chemotherapy and Hypomethylating agent Novel Therapy
More informationThe Changing Face of MDS: Advances in Treatment
Thank you very much again for listening to me. We are going to be talking now in terms of therapy of MDS or The Changing Face of MDS Advances in Treatment. My name is Guillermo Garcia-Manero. I am a Professor
More informationDisclosure Slide. Research Support: Onconova Therapeutics, Celgene
Oral Rigosertib Combined with Azacitidine in Patients with Acute Myeloid Leukemia (AML) and Myelodysplastic Syndromes (MDS): Effects in Treatment Naïve and Relapsed- Refractory Patients Shyamala C. Navada,
More informationInnate Immunity Dysregulation in Myelodysplastic Syndromes. CONTRACTING ORGANIZATION: University of Texas MD Anderson Cancer Center Houston, TX 77030
AWARD NUMBER: W81XWH-12-1-0221 TITLE: Innate Immunity Dysregulation in Myelodysplastic Syndromes PRINCIPAL INVESTIGATOR: Yue Wei CONTRACTING ORGANIZATION: University of Texas MD Anderson Cancer Center
More informationCombination of Oral Rigosertib and Injectable Azacitidine in Patients with Myelodysplastic Syndromes (MDS)
Combination of Oral Rigosertib and Injectable Azacitidine in Patients with Myelodysplastic Syndromes (MDS) Shyamala C. Navada, MD 1, Guillermo Garcia-Manero, MD 2, Katherine Hearn, RN 2, Rosalie Odchimar-Reissig,
More informationEmerging Treatment Options for Myelodysplastic Syndromes
Emerging Treatment Options for Myelodysplastic Syndromes James K. Mangan, MD, PhD Assistant Professor of Clinical Medicine Abramson Cancer Center, University of Pennsylvania Please note that some of the
More informationIPSS Modified 7/27/2011. WHO-Based Prognostic Scoring System (WPSS)
Advances in MDS Treatment: What s on the Horizon? New Prognostic Models and Therapies Jason Gotlib, MD, MS Assistant Professor of Medicine (Hematology) Stanford Cancer Center AA&MDSIF July 3, 011 WHO-Based
More informationMyelodysplastic Syndromes. Post-ASH meeting 2014 Marie-Christiane Vekemans
Myelodysplastic Syndromes Post-ASH meeting 2014 Marie-Christiane Vekemans Agenda New biological developments Risk assessment and prognostic factors New therapeutic options Agenda New biological developments
More informationEmerging Treatment Options for Myelodysplastic Syndromes
Emerging Treatment Options for Myelodysplastic Syndromes James K. Mangan, MD, PhD Assistant Professor of Clinical Medicine Abramson Cancer Center, University of Pennsylvania Please note that some of the
More informationTreatment of Low-Blast Count AML. Maria Teresa Voso Dipartimento di Biomedicina e Prevenzione Università di Roma Tor Vergata
Treatment of Low-Blast Count AML Maria Teresa Voso Dipartimento di Biomedicina e Prevenzione Università di Roma Tor Vergata Definition of Low-Blast Count AML Blast counts 20-30%, or > 10%? v Retrospective
More informationMyelodysplastic Syndromes
IPSS cytogenetic subgroups good intermediate poor p(gray-test) =.132 1 2 3 4 5 6 Bone marrow blast count
More informationShyamala Navada, MD Icahn School of Medicine at Mount Sinai. 60th ASH Annual Meeting & Exposition 2018: San Diego, CA, USA 1
Phase 2 Expansion Study of Oral Rigosertib Combined with Azacitidine (AZA) in Patients with Higher-Risk (HR) Myelodysplastic Syndromes: Efficacy and Safety Results in HMA Treatment Naive & Relapsed/Refractory
More information[ NASDAQ: MEIP ] Analyst & Investor Event December 8, 2014
[ NASDAQ: MEIP ] Analyst & Investor Event December 8, 2014 Forward-Looking Statements These slides and the accompanying oral presentation contain forward-looking statements. Actual events or results may
More informationTreating Higher-Risk MDS. Case presentation. Defining higher risk MDS. IPSS WHO IPSS: WPSS MD Anderson PSS
Treating Higher-Risk MDS Eyal Attar, M.D. Massachusetts General Hospital Cancer Center eattar@partners.org 617-724-1124 Case presentation 72 year old man, prior acoustic neuroma WBC (X10 3 /ul) 11/08 12/08
More informationChronic Myeloid Leukemia Outlook: The Future of CML Therapy
Chronic Myeloid Leukemia Outlook: The Future of CML Therapy Neil Shah, MD PhD Edward S. AgenoDistinguished Professor in Hematology/Oncology UCSF School of Medicine San Francisco, California Progression
More informationEHA 2017 Abstracts: 4 Abstracts ( 1 Oral Presentation, 2 EPosters, 1 Publication)
EHA 2017 Abstracts: 4 Abstracts ( 1 Oral Presentation, 2 EPosters, 1 Publication) ORAL RIGOSERTIB COMBINED WITH AZACITIDINE IN PATIENTS WITH ACUTE MYELOID LEUKEMIA (AML) AND MYELODYSPLASTIC SYNDROMES (MDS):
More informationSummary of Key AML Abstracts Presented at the European Hematology Association (EHA) June 22-25, 2017 Madrid, Spain
Summary of Key AML Abstracts Presented at the European Hematology Association (EHA) June 22-25, 2017 Madrid, Spain EHA 2017 ANNUAL MEETING: ABSTRACT SEARCH PAGE: https://learningcenter.ehaweb.org/eha/#!*listing=3*browseby=2*sortby=1*media=3*ce_id=1181*label=15531
More informationManagement of low and high risk MDS
Management of low and high risk MDS D.Selleslag AZ Sint-Jan Brugge, Belgium Brussels, 4th October 2014 Low / int 1 risk MDS Improve QOL Improve cytopenia Int 2 / high risk MDS Delay progression To AML
More informationMolecular Genetic Testing to Predict Response to Therapy in MDS
Molecular Genetic Testing to Predict Response to Therapy in MDS Rafael Bejar MD, PhD Bone Marrow Failure Disease Scientific Symposium Rockville, MD March 18 th, 2016 Overview Response Criteria Lenalidomide
More informationA CD123-targeting Antibody-Drug Conjugate (ADC), IMGN632, designed to eradicate Acute Myeloid Leukemia (AML) cells while sparing normal bone marrow
A CD123-targeting Antibody-Drug Conjugate (ADC), IMGN632, designed to eradicate Acute Myeloid Leukemia (AML) cells while sparing normal bone marrow Yelena Kovtun, Gregory Jones, Charlene Audette, Lauren
More informationSelinexor is an oral, slowly-reversible, first-inclass Selective Inhibitor of Nuclear Export (SINE)
Selinexor, a First-in-Class XPO1 Inhibitor, Is Efficacious and Tolerable in Patients with Myelodysplastic Syndromes (MDS) Refractory to Hypomethylating Agents Justin Taylor, MD, Morgan Coleman, MPH, Kelsey
More informationEmerging Treatment Options for Myelodysplastic Syndromes
Emerging Treatment Options for Myelodysplastic Syndromes James K. Mangan, MD, PhD Assistant Professor of Clinical Medicine Abramson Cancer Center, University of Pennsylvania Please note that some of the
More informationLa lenalidomide: meccanismo d azione e risultati terapeutici. F. Ferrara
La lenalidomide: meccanismo d azione e risultati terapeutici F. Ferrara MDS: new treatment goals Emerging treatment options expected to facilitate shift from supportive care to active therapy in MDS New
More informationPersonalized Therapy in Adult Acute Lymphocytic Leukemia: Path to the Cure. Elias Jabbour M.D
Personalized Therapy in Adult Acute Lymphocytic Leukemia: Path to the Cure Elias Jabbour M.D. 3-10-2018 Disclosures Elias Jabbour has a financial interest/relationship or affiliation in the form of: Consultant:
More informationMDS overview 전남대학교김여경
MDS overview 전남대학교김여경 2008 WHO Classification of MDS Name Abbreviation Key Feature Pts, % Refractory cytopenia, with unlineage, dysplasia Refractory anemia with ring sideroblasts RA Anemia and erythroid
More informationDisrupting the Cell Cycle to Treat AML and MDS Rodman & Renshaw Conference
CYC 682 Disrupting the Cell Cycle to Treat AML and MDS Rodman & Renshaw Conference September 2014 Disclaimer This presentation contains forward-looking statements within the meaning of the safe harbor
More informationMDS FDA-approved Drugs
MDS: Current Thinking on the Disease, Diagnosis, and Treatment Mikkael A. Sekeres, MD, MS Associate Professor of Medicine Director, Leukemia Program Dept of Hematologic Oncology and Blood Disorders Taussig
More informationNew and Emerging Strategies in the Treatment of Patients with Higher risk Myelodysplastic Syndromes (MDS)
Welcome to Managing Myelodysplastic Syndromes. My name is David Steensma. I am an Associate Professor of Medicine at Harvard Medical School and a faculty member in the Adult Leukemia Program at Dana Farber
More informationAML in elderly. D.Selleslag AZ Sint-Jan Brugge, Belgium 14 December 2013
AML in elderly D.Selleslag AZ Sint-Jan Brugge, Belgium 14 December 2013 AML is predominantly a disease of the elderly incidence 2 3/100.000 SEER Cancer Statistics, National Cancer Institute, USA 2002 2006
More informationOverview. Myelodysplastic Syndromes: What s on the Horizon? Molecular Mutations in MDS. Refining Risk Models. Incorporating Mutational Data
Myelodysplastic Syndromes: What s on the Horizon? Vu H. Duong, MD, MS Assistant Professor of Medicine University of Maryland July 16, 2016 Overview Refining Risk models Specific Therapeutic Areas of Need
More informationMyelodysplastic syndromes post ASH Dominik Selleslag AZ Sint-Jan Brugge
Myelodysplastic syndromes post ASH 2016 Dominik Selleslag AZ Sint-Jan Brugge Why did they put MDS at the end of the meeting? Possible explanations Least fascinating disease without progress? Poor speaker?
More informationPathogenesis and management of CMML
Pathogenesis and management of CMML Raphaël Itzykson, Hôpital Saint-Louis, Paris International Conference of the Korean Society of Hematology March 29th 2018 대한혈액학회 Korean Society of Hematology COI disclosure
More informationMyelodysplastic syndromes: 2018 update on diagnosis, risk-stratification and management
Received: 2 October 2017 Accepted: 2 October 2017 DOI: 10.1002/ajh.24930 ANNUAL CLINICAL UPDATES IN HEMATOLOGICAL MALIGNANCIES Myelodysplastic syndromes: 2018 update on diagnosis, risk-stratification and
More informationCause of Death in Patients With Lower-Risk Myelodysplastic Syndrome
Original Article Cause of Death in Patients With Lower-Risk Myelodysplastic Syndrome Farshid Dayyani, MD, PhD 1 ; Anthony P. Conley, MD 1 ; Sara S. Strom, PhD 2 ; William Stevenson, MBBS, PhD 3 ; Jorge
More informationRandomized phase 2 study of low-dose decitabine vs low-dose azacitidine in lower-risk MDS and MDS/MPN
Regular Article CLINICAL TRIALS AND OBSERVATIONS Randomized phase 2 study of low-dose decitabine vs low-dose azacitidine in lower-risk MDS and MDS/MPN Elias Jabbour, 1 Nicholas J. Short, 1 Guillermo Montalban-Bravo,
More informationNature Immunology: doi: /ni Supplementary Figure 1. Characteristics of SEs in T reg and T conv cells.
Supplementary Figure 1 Characteristics of SEs in T reg and T conv cells. (a) Patterns of indicated transcription factor-binding at SEs and surrounding regions in T reg and T conv cells. Average normalized
More informationOn Behalf of the SGI-110 Investigative Team
First clinical results of a randomized phase 2 study of SGI-110, a novel subcutaneous hypomethylating agent, in 102 patients with Intermediate or High Risk MDS or CMML n Behalf of the SGI-110 Investigative
More informationENASIDENIB IN MUTANT-IDH2 RELAPSED OR REFRACTORY ACUTE MYELOID LEUKEMIA (R/R AML): RESULTS OF A PHASE 1 DOSE- ESCALATION AND EXPANSION STUDY
ENASIDENIB IN MUTANT-IDH2 RELAPSED OR REFRACTORY ACUTE MYELOID LEUKEMIA (R/R AML): RESULTS OF A PHASE 1 DOSE- ESCALATION AND EXPANSION STUDY Eytan M. Stein, Courtney D. DiNardo, Daniel A. Pollyea, Amir
More informationSafety and Efficacy of Venetoclax Plus Low-Dose Cytarabine in Treatment-Naïve Patients Aged 65 Years With Acute Myeloid Leukemia
Safety and Efficacy of Venetoclax Plus Low-Dose Cytarabine in Treatment-Naïve Patients Aged 65 Years With Acute Myeloid Leukemia Abstract 102 Wei AH, Strickland SA, Roboz GJ, Hou J-Z, Fiedler W, Lin TL,
More informationINTRODUCTION TO CYTOGENETICS AND MOLECULAR TESTING IN MDS
INTRODUCTION TO CYTOGENETICS AND MOLECULAR TESTING IN MDS Saturday, September 29, 2018 Cyrus C. Hsia, HBSc, MD, FRCPC Associate Professor of Medicine, Schulich School of Medicine and Dentistry, Western
More informationAcute Myeloid Leukemia: State of the Art in 2018
Acute Myeloid Leukemia: State of the Art in 2018 Harry P. Erba, MD, PhD Professor, Department of Medicine Director, Leukemia Program Duke University Durham, NC Treatment Paradigm of Adults with AML Fit
More informationTherapeutic and Prognostic Role of Epigenetic Abnormalities in MDS. Stephen D. Nimer, MD Sylvester Comprehensive Cancer Center December 5, 2014
Therapeutic and Prognostic Role of Epigenetic Abnormalities in MDS Stephen D. Nimer, MD Sylvester Comprehensive Cancer Center December 5, 2014 DISCLOSURE I have no relevant financial relationships to disclose.
More informationMaintaining Long-Term Efficacy in the Elderly MDS Patient with Poor Performance Status
Hi, my name is Dr. Hetty Carraway. I am a staff physician at the Taussig Cancer Institute at the Cleveland Clinic. Welcome to Managing MDS. 1 As you all are aware, many of our patients with MDS are in
More informationMyelodysplastic Syndromes: Understanding your diagnosis and current and emerging treatments
Myelodysplastic Syndromes: Understanding your diagnosis and current and emerging treatments Shyamala Navada, M.D., MSCR Assistant Professor Icahn School of Medicine at Mount Sinai Tisch Cancer Institute
More informationNew treatment strategies in myelodysplastic syndromes and acute myeloid leukemia van der Helm, Lidia Henrieke
University of Groningen New treatment strategies in myelodysplastic syndromes and acute myeloid leukemia van der Helm, Lidia Henrieke IMPORTANT NOTE: You are advised to consult the publisher's version
More informationRefining Prognosis. Overview. Low Blood Counts. Low Blood Counts. High Risk MDS and Novel Therapy: What s on the Horizon? 3/2/2016
High Risk MDS and Novel Therapy: What s on the Horizon? Rafael Bejar MD, PhD Aplastic Anemia & MDS International Foundation Regional Patient and Family Conference March 19 th, 216 Overview Refining Prognosis
More informationANCO 2015: Treatment advances in acute leukemia
ANCO 2015: Treatment advances in acute leukemia Michaela Liedtke, MD Stanford, CA September 12, 2015!" Disclosures Research Support/P.I. Employee Consultant Major Stockholder Speakers Bureau Steering Committee
More informationOutline. Case Study 5/17/2010. Treating Lower-Risk Myelodysplastic Syndrome (MDS) Tapan M. Kadia, MD Department of Leukemia MD Anderson Cancer Center
Treating Lower-Risk Myelodysplastic Syndrome (MDS) Tapan M. Kadia, MD Department of Leukemia MD Anderson Cancer Center Outline Case Study What is lower-risk MDS? Classification systems Prognosis Treatment
More informationMyelodysplastic syndromes Impact of Biology. Lionel Adès Hopital Saint Louis Groupe Francophone des SMD. Épidémiologie
Myelodysplastic syndromes Impact of Biology Lionel Adès Hopital Saint Louis Groupe Francophone des SMD Épidémiologie Incidence : 3 à 6 / 100 000 hab. / An Prédomine chez les sujets âgés Augmentation de
More informationMyelodyplastic Syndromes Paul J. Shami, M.D.
Myelodyplastic Syndromes Paul J. Shami, M.D. Professor of Hematology, University of Utah Member, Huntsman Cancer Institute Objectives Define Myelodysplastic Syndromes (MDS) Explain how MDS are diagnosed
More informationKevin Kelly, MD, Phd Acute Myeloid and Lymphoid Leukemias
Kevin Kelly, MD, Phd Acute Myeloid and Lymphoid Leukemias Relevant financial relationships in the past twelve months by presenter or spouse/partner. Speakers bureau: Novartis, Janssen, Gilead, Bayer The
More informationDr Kavita Raj Consultant Haematologist Guys and St Thomas Hospital
Dr Kavita Raj Consultant Haematologist Guys and St Thomas Hospital IPSS scoring system Blood counts Bone marrow blast percentage Cytogenetics Age as a modulator of median survival IPSS Group Median Survival
More informationANCO Hematological Malignancies Update: The year in review. Midostaurin Vyxeos Gemtuzumab ozogamicin Enasidenib. The year in preview
ANCO Hematological Malignancies Update: Gabriel Mannis, MD Assistant Professor, and Marrow Co-Director, Cancer Immunotherapy Clinic Acute Leukemia Sacramento, CA June 16, 2018 OVERVIEW Overview The year
More informationUnderstanding & Treating Myelodysplastic Syndrome (MDS)
Understanding & Treating Myelodysplastic Syndrome (MDS) Casey O Connell, MD Associate Professor of Clinical Medicine Jane Anne Nohl Division of Hematology Keck School of Medicine of USC Let s Look at Our
More informationKEY WORDS: CRp, Platelet recovery, AML, MDS, Transplant
Platelet Recovery Before Allogeneic Stem Cell Transplantation Predicts Posttransplantation Outcomes in Patients with Acute Myelogenous Leukemia and Myelodysplastic Syndrome Gheath Alatrash, Matteo Pelosini,
More informationIDH1 AND IDH2 MUTATIONS
Mutant Isocitrate Dehydrogenase (midh) Inhibitors, Enasidenib or Ivosidenib, in Combination with Azacitidine (AZA): Preliminary Results of a Phase 1b/2 Study in Patients with Newly Diagnosed Acute Myeloid
More informationEnasidenib Monotherapy is Effective and Well-Tolerated in Patients with Previously Untreated Mutant-IDH2 Acute Myeloid Leukemia
Enasidenib Monotherapy is Effective and Well-Tolerated in Patients with Previously Untreated Mutant-IDH2 Acute Myeloid Leukemia Pollyea DA 1, Tallman MS 2,3, de Botton S 4,5, DiNardo CD 6, Kantarjian HM
More informationAcute Myeloid Leukemia Progress at last
Acute Myeloid Leukemia Progress at last Bruno C. Medeiros, MD September 9, 217 Introduction Mechanisms of leukemogenesis Emerging therapies in AML Previously untreated AML Relapsed and refractory patients
More informationMyelodyspastic Syndromes
Myelodyspastic Syndromes SUPPLEMENTARY APPENDIX Complex or monosomal karyotype and not blast percentage is associated with poor survival in acute myeloid leukemia and myelodysplastic syndrome patients
More informationAcute Leukemia From Precision Medicine to ImmunoRx
Acute Leukemia From Precision Medicine to ImmunoRx Hagop M. Kantarjian, MD Professor and Chair, Department of Leukemia Samsung Distinguished Leukemia Chair in Cancer Medicine The University of Texas MD
More informationLet s Look at Our Blood
Let s Look at Our Blood Casey O Connell, MD Associate Professor of Clinical Medicine Jane Anne Nohl Division of Hematology Keck School of Medicine of USC 10,000,000,000 WBCs/day Bone Marrow: The Blood
More informationMDS 101. What is bone marrow? Myelodysplastic Syndrome: Let s build a definition. Dysplastic? Syndrome? 5/22/2014. What does bone marrow do?
101 May 17, 2014 Myelodysplastic Syndrome: Let s build a definition Myelo bone marrow Gail J. Roboz, M.D. Director, Leukemia Program Associate Professor of Medicine What is bone marrow? What does bone
More informationCREDIT DESIGNATION STATEMENT
CME Information LEARNING OBJECTIVES Recall the dose-limiting toxicity and preliminary clinical response results with 14- and 21-day extended treatment schedules of daily oral azacitidine. Apply new research
More informationRigoser2b Strategies to Rasopathies and JMML
Rigoser2b Strategies to Rasopathies and JMML Steven Fruchtman, M.D. Chief Medical Officer & Senior Vice President, Research & Development Rasopathy Network, Orlando July 28, 2017 1 DESCRIPTION OF RIGOSERTIB
More informationDana-Farber Cancer Institute, Boston, MA; 2 City of Hope National Medical Center, Duarte, CA; 3 Roswell Park Cancer Institute, Buffalo, NY; 4
Results from Ongoing Phase 2 Trial of SL-401 As Consolidation Therapy in Patients with Acute Myeloid Leukemia (AML) in Remission with High Relapse Risk Including Minimal Residual Disease (MRD) Andrew A.
More informationNew drugs in Acute Leukemia. Cristina Papayannidis, MD, PhD University of Bologna
New drugs in Acute Leukemia Cristina Papayannidis, MD, PhD University of Bologna Challenges to targeted therapy in AML Multiple subtypes based upon mutations/cytogenetic aberrations No known uniform genomic
More informationNon-transplant Therapy for MDS. Bart Scott, MD Associate Member, FHCRC Associate Professor, UWMC
Non-transplant Therapy for MDS Bart Scott, MD Associate Member, FHCRC Associate Professor, UWMC MDS Treatment Algorithm Asymptomatic Symptomatic Bone Marrow Function Low/Int-1 Int-2/High Observation Cytokine
More informationOn behalf of Study SGI Investigators Team
Long Term Survival and Clinical Complete Responses of Various Prognostic Subgroups in 103 Relapsed/Refractory Acute Myeloid Leukemia (r/r AML) Patients Treated with Guadecitabine (SGI-110) in Phase 2 Studies
More informationPiper Jaffray Healthcare Conference
Piper Jaffray Healthcare Conference John Scarlett, M.D. President and CEO, Geron Corporation November 2018 Forward-Looking Statements Except for statements of historical fact, the statements contained
More informationNew concepts in the management of elderly patients with AML
New concepts in the management of elderly patients with AML Martha L. Arellano, MD Associate Professor of Hematology/Oncology Director, Hematology & Medical Oncology Fellowship Program Winship Cancer Institute
More informationYour Speaker. Outline 10/2/2017. Myelodysplastic Syndromes and Myeloid Neoplasms. Introduction and classifications Epidemiology Presentation Workup
Myelodysplastic Syndromes and Myeloid Neoplasms Abdulraheem Yacoub, MD Associate Professor Of Medicine Clinical Director of Ambulatory Hematology clinics The University of Kansas Cancer Center Your Speaker
More informationThe immunomodulatory agents lenalidomide and thalidomide for treatment of the myelodysplastic syndromes: A clinical practice guideline
Critical Reviews in Oncology/Hematology 85 (2013) 162 192 The immunomodulatory agents lenalidomide and thalidomide for treatment of the myelodysplastic syndromes: A clinical practice guideline Heather
More informationMyelodysplastic Syndromes: Hematopathology. Analysis of SHIP1 as a potential biomarker of Disease Progression
Myelodysplastic Syndromes: Hematopathology. Analysis of SHIP1 as a potential biomarker of Disease Progression Carlos E. Bueso-Ramos, M.D., Ph.D Department of Hematopathology The University of Texas M.
More informationInotuzumab Ozogamicin in ALL. Hagop Kantarjian M.D. May 2016 Bologna, Italy
Inotuzumab Ozogamicin in ALL Hagop Kantarjian M.D. May 2016 Bologna, Italy Immuno Oncology in ALL Monoclonals + cytotoxic agents e.g.inotuzumab Bispecific monoclonals (CD3 + CD19) e.g.blinatumomab Modified
More informationCharacteristics, clinical outcome, and prognostic significance of IDH mutations in AML
Characteristics, clinical outcome, and prognostic significance of IDH mutations in AML AJH Courtney D. DiNardo, 1 * Farhad Ravandi, 1 Sam Agresta, 2 Marina Konopleva, 1 Koichi Takahashi, 1 Tapan Kadia,
More informationCML: Yesterday, Today and Tomorrow. Jorge Cortes, MD Chief CML Section Department of Leukemia The University of Texas, M.D. Anderson Cancer Center
CML: Yesterday, Today and Tomorrow Jorge Cortes, MD Chief CML Section Department of Leukemia The University of Texas, M.D. Anderson Cancer Center Five Years of Signal Transduction Inhibition The Beginning
More informationA paradigm shift in the therapy of low blast count acute myeloid leukemia. Valeria Santini UF Ematologia, Università di Firenze
A paradigm shift in the therapy of low blast count acute myeloid leukemia Valeria Santini UF Ematologia, Università di Firenze Patients (%) AML is predominantly a disease of the elderly 40 69% of patients
More informationAML IN OLDER PATIENTS Whenever possible, intensive induction therapy should be considered
AML IN OLDER PATIENTS Whenever possible, intensive induction therapy should be considered Charles A. Schiffer, M.D. Karmanos Cancer Institute Wayne State University School of Medicine Detroit, MI WHY ARE
More informationEvolving Targeted Management of Acute Myeloid Leukemia
Evolving Targeted Management of Acute Myeloid Leukemia Jessica Altman, MD Robert H. Lurie Comprehensive Cancer Center of Northwestern University Learning Objectives Identify which mutations should be assessed
More informationMeet-the-Expert: AML Treating older patients with AML
Meet-the-Expert: AML Treating older patients with AML Sergio Amadori Tor Vergata University Hospital Rome Istanbul 2012 AML in older patients Poor prognosis Minority treated with intensive Cx Treatment
More informationUse of TPO mimetics for Indications Other Than ITP
Use of TPO mimetics for Indications Other Than ITP Mazyar Shadman, MD, MPH Discussant: Siobán Keel, MD Hematology Fellows Conference June 28, 2013 Thrombopoietin (TPO) and other c mpl ligands TPO mimetics
More informationClinical Trials What are they?
Newer Agents And Combinations in Myelodysplastic Syndromes Ruben A. Mesa, MD Mayo Clinic Arizona David P. Steensma, MD Dana-Farber Cancer Institute What are they? Biomedical or health-related related research
More informationMyelodysplastic Syndrome
Myelodysplastic Syndrome A Family-Oriented Approach on Diagnosis and Treatment Options Cecilia Arana Yi, MD Assistant Professor MDS Patient & Family/Caregiver Forum March 3, 2018 Quote of the Day There
More informationAre we always prolonging survival?
New therapies for myelodysplastic syndromes beyond hypomethylating agents and IMIDs Valeria Santini UF Ematologia, Università di Firenze Lisbon, May 4 th, 2012 Are we always prolonging survival? 1 Survival
More informationTreatment of low risk MDS
Treatment of low risk MDS Matteo G Della Porta Cancer Center IRCCS Humanitas Research Hospital & Humanitas University Rozzano Milano, Italy matteo.della_porta@hunimed.eu International Prognostic Scoring
More informationMDS-004 Study: REVLIMID (lenalidomide) versus Placebo in Myelodysplastic Syndromes with Deletion (5q) Abnormality
MDS-4 Study: REVLIMID (lenalidomide) versus Placebo in Myelodysplastic Syndromes with Deletion (5q) Abnormality TABLE OF CONTENTS Section 1. Executive Summary Section 2. Background Section
More informationLong-term innate immune memory via effects on bone marrow progenitors
Long-term innate immune memory via effects on bone marrow progenitors Helen S Goodridge, PhD helen.goodridge@csmc.edu Regenerative Medicine Institute, Cedars-Sinai Medical Center, Los Angeles, USA Fondation
More informationsequences of a styx mutant reveals a T to A transversion in the donor splice site of intron 5
sfigure 1 Styx mutant mice recapitulate the phenotype of SHIP -/- mice. (A) Analysis of the genomic sequences of a styx mutant reveals a T to A transversion in the donor splice site of intron 5 (GTAAC
More informationNovità nelle MDS. Matteo G Della Porta. Cancer Center IRCCS Humanitas Research Hospital & Humanitas University Rozzano Milano, Italy
Novità nelle MDS Matteo G Della Porta Cancer Center IRCCS Humanitas Research Hospital & Humanitas University Rozzano Milano, Italy matteo.della_porta@hunimed.eu Outline ARCH Predictive value of somatic
More informationPrognostic Scoring Systems for Therapeutic Decision Making in MDS. Peter Greenberg, MD Stanford University Cancer Center Stanford, CA
Prognostic Scoring Systems for Therapeutic Decision Making in MDS Peter Greenberg, MD Stanford University Cancer Center Stanford, CA DISCLOSURE I have no relevant financial relationships to disclose. MDSs:
More informationCML: Living with a Chronic Disease
CML: Living with a Chronic Disease Jorge Cortes, MD Chief, CML and AML Sections Department of Leukemia M. D. Anderson Cancer Center Houston, Texas Survival in Early Chronic Phase CML TKI Interferon Chemotherapy
More informationPersonalized Therapy for Acute Myeloid Leukemia. Patrick Stiff MD Loyola University Medical Center
Personalized Therapy for Acute Myeloid Leukemia Patrick Stiff MD Loyola University Medical Center 708-327-3216 Major groups of Mutations in AML Targets for AML: Is this Achievable? Chronic Myeloid Leukemia:
More informationMYELODYSPLASTIC SYNDROME. Vivienne Fairley Clinical Nurse Specialist Sheffield
MYELODYSPLASTIC SYNDROME Vivienne Fairley Clinical Nurse Specialist Sheffield MDS INCIDENCE 1/100,000/YEAR 3,250/YEAR MEDIAN AGE 70 MDS HYPO OR HYPERCELLULAR BONE MARROW BLOOD CYTOPENIAS (EARLY STAGES
More informationABSTRACT. Clinical Research Paper
/, 2017, Vol. 8, (No. 45), pp: 79414-79424 Can we consider discontinuation of hypomethylating agents in patients with myelodysplastic syndrome : a retrospective study from The Korean Society of Hematology
More informationMyelodysplastic Syndromes: Challenges to Improving Patient and Caregiver Satisfaction
Supplement issue Myelodysplastic Syndromes: Challenges to Improving B. Douglas Smith, MD Division of Hematologic Malignancies, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Johns Hopkins
More information